RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Donor cells join forces with antibody to fight tough lymphomas
Disease control Recruiting nowThis early-phase trial tests a combination of donated natural killer (NK) immune cells and a drug called mogamulizumab for people with certain T-cell lymphomas that have returned or not responded to prior treatment. The study aims to find the safest dose and see if the combinatio…
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: John Reneau • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Virus-Based therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:05 UTC